Latest News
Aktis Oncology, Inc.
- Aktis Oncology, Inc. Estimates – NASDAQ:AKTS
- Aktis Oncology (AKTS) - What Are Researchers Saying About This Stock?
- Aktis Oncology: Padcev Is Building The Market It Wants
- Aktis Oncology undervalued despite strong cash and promising drug programs, with key data expected in 2027
- 93,434 Aktis Oncology $AKTS Shares Acquired by Mirador Capital Partners LP
- Aktis Oncology's (AKTS) "Outperform" Rating Reaffirmed at Wedbush
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
- Form 144 AKTIS ONCOLOGY INC For: 26 September By Investing.com
- Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages
- Aktis Oncology (AKTS) medical chief exercises options and sells shares under a trading plan.
Headlines from the last 30 days, linking to the original publishers. See all market news →